Centessa Pharmaceuticals Plc, the newly formed biopharma company backed by private equity firm General Atlantic, said on Monday it was aiming for a valuation of up to $1.7 billion in its initial public offering in the United States.
Formed in October, Centessa received $250 million funding in January. It is also backed by venture capital firm Index Ventures and life sciences-focused investment firm Medicxi.
Moncef Slaoui, formerly the chief scientific adviser for the U.S. government’s Operation Warp Speed COVID-19 vaccine development program, joined Centessa as its chief scientific officer in February.
Morgan Stanley, Goldman Sachs, Jefferies and Evercore ISI are the underwriters for the offering. Centessa said it would list on the Nasdaq under the symbol “CNTA”.
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.